Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT WITH JIANGSU ALPHAMAB FOR THE DEVELOPMENT AND COMMERCIALIZATION OF JSKN003 IN MAINLAND CHINA

VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT WITH JIANGSU ALPHAMAB FOR THE DEVELOPMENT AND COMMERCIALIZATION OF JSKN003 IN MAINLAND CHINA

September 30, 2024

a240930_00.png

a240930_01.png

Previous: VOLUNTARY ANNOUNCEMENT EXCLUSIVE LICENSE AGREEMENT FOR YS2302018 WITH ASTRAZENECA

Next: VOLUNTARY ANNOUNCEMENT - VALSARTAN LEVOAMLODIPINE MALEATE TABLETS OBTAINS CLINICAL TRIAL APPROVAL

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |

Wechat